Next Article in Journal
Current Status of Endolysin-Based Treatments against Gram-Negative Bacteria
Next Article in Special Issue
Metabolomic Profiling and Biological Activities of Pleurotus columbinus Quél. Cultivated on Different Agri-Food Byproducts
Previous Article in Journal
Antibacterial Effect of Sodium Hypochlorite and EDTA in Combination with High-Purity Nisin on an Endodontic-like Biofilm Model
Previous Article in Special Issue
Growth Suppression of a Gingivitis and Skin Pathogen Cutibacterium (Propionibacterium) acnes by Medicinal Plant Extracts
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 10
Issue 9
10.3390/antibiotics10091142
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antibiofilm Potential of Medicinal Plants against Candida spp. Oral Biofilms: A Review

by
Rafaela Guimarães
1,†,
Catarina Milho
1,†,
Ângela Liberal
2,†,
Jani Silva
1,
Carmélia Fonseca
3,
Ana Barbosa
3,
Isabel C. F. R. Ferreira
2,
Maria José Alves
1,2,* and
Lillian Barros
2,*
1
AquaValor–Centro de Valorização e Transferência de Tecnologia da Água–Associação, Rua Dr. Júlio Martins n.º 1, 5400-342 Chaves, Portugal
2
Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal
3
Instituto Politécnico de Bragança, Escola Superior de Saúde (ESSa), Campus de Santa Apolónia, 5300-253 Bragança, Portugal
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Antibiotics 2021, 10(9), 1142; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10091142
Submission received: 23 August 2021 / Revised: 15 September 2021 / Accepted: 20 September 2021 / Published: 21 September 2021
(This article belongs to the Special Issue Antimicrobial Activity of Extracts from Plant)
Browse Figure
Versions Notes

Abstract

:
The use of natural products to promote health is as old as human civilization. In recent years, the perception of natural products derived from plants as abundant sources of biologically active compounds has driven their exploitation towards the search for new chemical products that can lead to further pharmaceutical formulations. Candida fungi, being opportunistic pathogens, increase their virulence by acquiring resistance to conventional antimicrobials, triggering diseases, especially in immunosuppressed hosts. They are also pointed to as the main pathogens responsible for most fungal infections of the oral cavity. This increased resistance to conventional synthetic antimicrobials has driven the search for new molecules present in plant extracts, which have been widely explored as alternative agents in the prevention and treatment of infections. This review aims to provide a critical view and scope of the in vitro antimicrobial and antibiofilm activity of several medicinal plants, revealing species with inhibition/reduction effects on the biofilm formed by Candida spp. in the oral cavity. The most promising plant extracts in fighting oral biofilm, given their high capacity to reduce it to low concentrations were the essential oils extracted from Allium sativum L., Cinnamomum zeylanicum Blume. and Cymbopogon citratus (DC) Stapf.

1. Introduction

Medicinal plants have been used for several centuries to treat a wide variety of ailments. In recent years, the investigation into molecules derived from these plants, which play a fundamental role in the resistance of various pathogens, has boosted the study of their antibacterial and/or antibiofilm properties [1,2,3]. Some plant compounds can interact with bacterial proteins and cell membrane structures, damaging them and reducing their fluidity, while inhibiting their nucleic acid synthesis and interfering with the energy metabolism of the microorganisms themselves [2,4,5]. Additionally, the study of the antibiofilm properties associated with these molecules has revealed that, in addition to their fungicidal/bactericidal effect, other underlying mechanisms can lead to biofilm suppression, namely, disturbances at the level of bacterial regulation mechanisms [6].
The biofilm is a more resistant form of microbial existence on solid surfaces and air–liquid interfaces in which microorganisms multiply in a matrix of self-produced extracellular polymeric substances (EPS) [7]. Its resistance is directly related to the natural survival characteristics of the microbial cells that live in these communities. The slower growth of cells associated with the biofilm, as opposed to free-living microbial cells, and the tight regulation of the cellular processes, stand out, and are mainly caused by the more restricted contact of the cells inside the biofilm with external nutrients. In addition, the presence of an EPS matrix that hinders the action of antimicrobials contributes even more to the resistance of biofilms, since this matrix acts as a diffusion barrier against small molecules [8,9].
Biofilms can be found in a variety of surfaces, both biotic and abiotic. Particularly in the oral cavity, biofilm can be found in the teeth and mucosal surfaces and are thought to consist of approximately 700 bacterial species, 100 fungal species, and some viruses [10]. Since these microorganisms coexist in the same environment, there is the possibility of interactions between different species, a factor that can make an oral infection more difficult to treat, creating an environment of protection and tolerance for microorganisms against conventional antimicrobial agents [11].
One of the main groups of microorganisms that can be found in the normal oral flora is the genus Candida, which is composed of dimorphic commensal yeast. Although Candida species are mainly nonpathogenic, when an imbalance in the oral microbiome occurs, they are the main pathogens responsible for the occurrence of fungal infections in the oral cavity [12]. One of the key virulence factors associated with these microorganisms is their ability to adhere to oral surfaces and form biofilms, which function as a reservoir for this type of fungi, both in teeth and mucosal surfaces [13,14]. Several factors contribute to the unbalanced colonization and biofilm formation in the oral cavity by Candida spp., namely, low salivary flow, low pH and poor oral hygiene among others [15]. As an opportunistic pathogen, this yeast can also cause disease when the host’s immune system is debilitated by the appearance of pathologies such as diabetes mellitus and Human Immunodeficiency Virus (HIV) infection, and by the use of broad-spectrum antibiotics, among others [16]. Additionally, as they are one of the largest acid producers in the oral cavity, Candida fungi can also be at the origin of dental caries through a localized infectious process [17,18,19].
Once the establishment of pathogenic oral biofilms occurs, the risk of the occurrence of systemic infections increases, as does the resistance of these infections to conventional antimicrobial therapies [20]. Currently, the treatment of Candida infections in the oral cavity is mostly done using broad-spectrum antimicrobials, however, conventional biocidal agents can cause substantial side effects if administered in high concentrations, including vomiting, diarrhea, mucosal desquamation, tooth discoloration, etc. [11,19]. Given the harmful effects of traditional antimicrobial agents, and the increasing microbial resistance to them, natural plant products have been pointed out as a safe and efficient alternative for the treatment of Candida infections in the oral cavity since, together with their anti-inflammatory, antioxidant, and analgesic properties, they also exert antimicrobial and antibiofilm effects over Candida spp [21].

2. The Bioactive Compounds of Plants

Folk knowledge about the medicinal use of plants has been transmitted for centuries [22]. In recent years, much of the ethnopharmaceutical research has been focused on more specific approaches in order to evaluate and understand the biological and pharmaceutical effects of medicinal and aromatic plants [22]. Plants are rich in a wide variety of secondary metabolites which play an important role in the defense against numerous pathogens. These molecules are also involved in adaptation to biotic and abiotic stresses, protection against ultraviolet radiation, oxidation of molecules, nutritional and water stresses, while performing functions at the tissue level structure, being able to add flavor and color to plant products [23].
Presently, about 200,000 different plant secondary metabolites have been isolated and identified [24]. They can be classified based on their chemical structures and/or biosynthetic pathways [25]. A simple classification includes three main groups: terpenoids (polymeric isoprene derivatives and biosynthesized from acetate via the mevalonic acid pathway), phenolics (biosynthesized from shikimate pathways, containing one or more hydroxylated aromatic ring), and alkaloids (nonprotein nitrogen-containing compounds, biosynthesized from amino acids, such as tyrosine) [26]. Terpenoids, the condensation products of C5 isoprene units, are the main components of plant volatiles and essential oils [27]. They present many important properties, including anti-insect, antimicrobial, antiviral, and antiherbivore properties [28]. Phenolic compounds are widely found in fruits, seeds, leaves, roots, and stems, and are known for their strong antioxidant ability and their anticancer, anti-inflammatory, hypolipidemic, and hypoglycemic properties [29,30]. They have at least one aromatic ring with one or more hydroxyl groups attached, ranging from low molecular weight molecules to large and complex ones [31]. Alkaloids are usually cyclic organic compounds that contain at least one nitrogen atom in an amine-type structure [32]. These compounds are known to possess varied biological activities such as antimicrobial and antimalarial properties, among others [33].
Many studies have been published regarding bioactive properties such as antioxidant [34,35], antitumoral [31,36], analgesic/anti-inflammatory [29,37], immunostimulant [38], antiseptic, and antimicrobial [39,40,41]. The antimicrobial and/or antibiofilm activity linked with some of these compounds is closely related to their ability to inhibit the synthesis of nucleic acids, disrupt the plasma membrane, inhibit efflux pumps, elicit mitochondrial disfunction, impair cell division and/or growth, and impair cell-wall formation, as shown in Figure 1 [42,43].
Given their strong bioactive potential, various types of phytocompounds are currently used in a wide range of fields such as food, pharmaceuticals, biomaterials, and environmental purification [44]. Regarding the ability of these compounds as antimicrobials, multiple studies have been conducted to determine their capability to fight oral infections caused by opportunistic pathogens such as Candida species [45,46,47,48]. The increased virulence of some Candida species such as Candida albicans is largely related to their ability to form biofilms which, as mentioned before, makes oral infections caused by these microorganisms very difficult to treat [49]. Taking this information into account, the use of plant-derived products to fight oral pathologies caused by Candida appears as an alternative to conventional antifungal therapy. In oral care, the use of natural products to prevent candidiasis is receiving much attention and many studies have reported the effects of medicinal plant extracts on the inhibition of oral pathogen growth and inhibition of surfaces adhesion to surfaces [50]. Some of the most prescribed antimycotic agents that are currently used target the synthesis of fungal cell membrane components that are not found in human cells, such as ergosterol [51]. However, there are few available antifungal compounds that show low levels of cytotoxicity, given the similarities between human and fungal cells, making it urgent to search for and identify new molecules capable of disrupting biofilms formed by Candida spp. and increase the arsenal of antifungal agents [52,53]. Knowing this, screening plants as potential sources of molecules with antifungal and/or antibiofilm properties can be considered an excellent approach to combat the formation of Candida spp. oral biofilms and the establishment of infections [54].

3. Opportunistic Fungal Infections Caused by Candida spp.

Currently, fungal infections affect millions of people every year, being the fourth leading cause of hematogenous infections worldwide. Candida spp., commensal microorganisms present in the normal microbial flora of the skin and mucosal surfaces (oral cavity, gastrointestinal tract, and vagina) of healthy individuals [55], are presented as the main responsible for the development of candidiasis, the most common invasive fungal disease in developed countries [56]. As commensals, Candida species are harmless; however, if the balance of normal flora is disrupted or immune defenses are compromised, these fungi can overrun the normal flora and cause disease. When the host’s immune status is impaired, two main types of Candida infection can be observed: superficial or invasive candidiasis. Superficial infections of the mucosal epithelial tissues are frequent in immunocompromised patients and include chronic atrophic stomatitis, chronic mucocutaneous candidiasis, and vulvovaginitis. In more severe cases, Candida species can enter the bloodstream (candidemia) and penetrate almost every organ in the body [57].
Seven Candida species are classified as clinically relevant, namely, C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, C. stellatoidea, C. kruseia, and C. kyfer, with the species C. albicans being the most relevant since it is the most often isolated from deeper tissues, blood, and organs [58,59].
Candidiasis has been related, majorly, to C. albicans species, a dimorphic fungal organism that is normally present in the oral cavity in a nonpathogenic state but which, under propitious conditions, can transmute into pathogenic hyphae form due to changes in the normal conditions of the oral cavity, especially in patients with reduced immune function or in antibiotic treatment [60,61,62]. A variety of local and systemic predisposing factors can lead to the transition from commensal to pathogenic Candida, namely the use of dentures, corticosteroid inhalers, and xerostomia, and systemic factors such as immunosuppressive states, HIV infection, malnutrition, diabetes, systemic chemotherapy, and radiotherapy, among others [63]. Therefore, about 65% of oral candidiasis are identified in the elderly, usually due to the use of dentures, and other pathologies associated with this age group, and about 16.7% in patients with hematological disorders [64]. Other factors, such as the diversity of microorganisms, the presence of saliva, vascularization, contamination by food residues, and trauma resulting from lack of hygiene, increase the inflammatory process, healing time, and patient discomfort [65,66].
Candida spp. express a variety of virulence factors so that it can cause disease. Biofilm formation in Candida spp. and the transition from planktonic to sessile form are mainly associated with a high resistance to antimicrobials. Other mechanisms include the expression of resistance genes, particularly those encoding efflux pumps, and the presence of persistent cells [67]. The interaction of bacteria and Candida within the biofilm is increasingly evident, however, the role of fungi in the progression of inflammation and the prognosis of oral infections remains uncertain [68].
Currently, there are only four main classes of antifungals in clinical use: azoles, polyenes, echinocandins, and pyrimidine analogs. The lack of antifungal diversity dramatically decreases the chances of treatment success and increases the probabilities of a fatal outcome if the pathogen is resistant to one or more drugs [69]. Therefore, the search for alternative products and phytochemicals isolated from plants and used in traditional medicine is considered a good alternative to conventional synthetic drugs, offering a wide range of molecules with antimicrobial and/or antibiofilm properties to combat oral candidiasis.

4. Plant Extracts against Oral Biofilm Formed by Candida spp.

Most of the available antifungals are either ineffective against Candida biofilms or exhibit activity at very high concentrations [70]. Concerning microbial resistance, pharmacotherapy has reached its limit, threatening the effective prevention and treatment of an ever-increasing range of infections. These limitations have led to the search for novel molecules with antibiofilm potential. Plants are rich sources of bioactive molecules exhibiting various biological and pharmaceutical properties. Therefore, in recent years, new clinical approaches using natural phytocompounds have been the subject of several types of research, considering the composition of natural plant products in molecules with antimicrobial and/or antibiofilm potential. Table 1 presents some of the plant species whose extracts hold compounds with antifungal/antibiofilm activity against Candida spp. Moreover, extracts able to inhibit biofilm formation and/or eradication in more than 99%, at concentrations ≤ 1 mg∙mL−1, were chosen for discussion.
Allium sativum L. (Amaryllidaceae) is an aromatic herbaceous annual plant, one of the oldest authenticated and most important herbs that have been used since ancient times in traditional medicine. It is one of the most described plant species with proven antifungal, antimicrobial, anti-aging, as well as anticancer properties, which have been confirmed by epidemiological data from human clinical studies [71]. This specie and its active components have been also reported to reduce the risk of diabetes and cardiovascular diseases [72,73]. A. sativum antibiofilm properties against oral cavity yeast were studied by Fahim et al. [74] who demonstrated that, for a concentration of 8.00 µg∙mL−1, A. sativum L. essential oil presented > 99.9% of growth reduction on biofilm of C. albicans ATCC 14053. The ability of this essential oil to inhibit biofilm formation seems to be correlated with its phenolic profile, with allicin, alliin and ajoene being the major compounds found in it [75].
Essential oils from some plants have shown high antifungal and/or antibiofilm activity against Candida species. An example of this are the species of Cinnamomum cassia (L.) J. Presl, Cinnamomum zeylanicum Blume, Cymbopogon citratus (DC.) Stapf, Cymbopogon nardus L. Rendle, and Cymbopogon winterianus Jowitt.
C. cassia (L.) J.Presl (Lauraceae), also known as “Chinese cinnamon,” is a well-known aromatic plant that has been widely cultivated and utilized to treat diabetes, ovarian cysts, stomach spasms, kidney disorders, high blood pressure, and menstrual disorders [76], and presents antimicrobial, antioxidant and antifungal properties [77]. C. zeylanicum Blume (Lauraceae) is an ever-green perennial plant that is used as a culinary herb [78]. This species presents several pharmacological properties such as antimicrobial, antioxidant, antifungal, and anticancer [79]. When it comes to oral health, a study performed by Almeida et al. [80] demonstrated that C. cassia essential oil, at a concentration of 1.00 mg∙mL−1, exerts more than 99.9% reduction in oral biofilm formation caused by C. albicans ATCC 90028, while C. zeylanicum, at a concentration of 1.6 µg∙mL−1, leads to more than 99.75% reduction in oral biofilm formation caused by C. albicans ATCC 10231. The high percentage of biofilm reduction shown by these two plants is attributed to the major phytocompound found in both species, the cinnamaldehyde. Cinnamaldehyde is a phenylpropanoid that may act on the cell membrane, likely binding to enzymes involved in the formation of the cytoplasmic membrane in fungal cells [81].
C. citratus (DC.) Stapf (Poaceae), commonly known as lemongrass, is an aromatic plant widely distributed around the world. It is used as a food flavouring, and is commonly consumed in teas and soups, but it may also be served with poultry, fish, beef, and seafood. Lemongrass essential oil exhibits a number of biological activities, including antioxidant [82], anti-inflammatory [83], antimicrobial [84], antifungal, and antibiofilm properties [85]. Almeida et al. [80] used the essential oil from C. citratus as an antifungal agent against C. albicans ATCC 10231 biofilms, and reported that, at the concentration of 6.4 µg∙mL−1, this essential oil was able to reduce the number of viable cells present in the biofilm by 99.79%. In this case, citral and neral were two of the main compounds found, which are known to hold antifungal properties [86,87].
C. nardus L. (Poaceae), popularly known as citronella, is a grass cultivated in subtropical and tropical regions of Asia, Africa, and America, including Brazil [88], The essential oil extracted from its leaves is commonly used in perfumes, the production of cosmetics, and as an insect repellent. Several studies have demonstrated the antiviral [89], antibacterial [90], and antifungal activities [91] of this oil. C. winterianus Jowitt (Poaceae) is an important aromatic plant cultivated in India and Brazil. In folk medicine, it is used for the treatment of anxiety, as a sedative, and for pain disorders [92]. Some studies demonstrated that the plant has anticonvulsant effects [93], anti-larvicidal effects against Aedes aegypti [94], and antibacterial and antifungal effects, including anti-Candida action [95]. The essential oils extracted from C. nardus L. and C. winterianus Jowitt species showed, in different studies, to be highly effective in combating C. albicans oral biofilms. C. nardus showed, at a concentration of 32.0 µg∙mL−1, an adherence inhibition of C. albicans ATCC 76645 higher than 99.0%, [68] and the application of C. winterianus essential oil, at a concentration of 1.00 mg∙mL−1, led to a reduction of C. albicans ATCC 90028 oral biofilm formation by more than 99.0%. In both species, the authors attributed the antibiofilm potential to the main compound identified in these species, namely citronellal. Citronellal is known to affect C. albicans cell growth by interfering with cell-cycle progression through the arrest of cells in S phase and affecting membrane integrity [96].
Solidago virgaurea L. (Asteraceae), commonly known as goldenrod, is a medicinal plant that is common throughout the world. In the literature, this plant is described as possessing a variety of medicinal properties such as antioxidant, anti-inflammatory, analgesic, spasmolytic, antihypertensive, antibacterial, antifungal and antitumor, among others [97]. Chevalier et al. [98] evaluated the effect of the extracts from two S. virgaurea subspecies, S. virgaurea subsp. alpestris and S. virgaurea subsp. virgaurea, on C. albicans oral biofilm growth. The results obtained showed that, at an extract concentration of 250 µg∙mL−1, S. virgaurea subsp. alpestris inhibition of oral biofilms from C. albicans IM003 was higher than 99.5%, and that S. virgaurea subsp. virgaurea inhibited the oral biofilm formation by C. albicans IM001 by more than 99.2%. Regarding the chemical composition of this plant, the compounds usually found in S. virgaurea are saponins, which have been attributed to the ability to inhibit the transition from yeast to hyphal growth [98]. This attribution seems reasonable considering the inherent surfactant properties of saponins, as well as their iron chelator qualities, iron being necessary for the growth and development of Candida spp. [99].
Table
Table 1. Medicinal plants with antimicrobial/antibiofilm activity against oral Candida spp. and the respective bioactive compounds present in their extracts.
Table 1. Medicinal plants with antimicrobial/antibiofilm activity against oral Candida spp. and the respective bioactive compounds present in their extracts.
Plant NamePlant ExtractCompoundMicroorganismResults References
Antimicrobial ActivityAntibiofilm Activity
Allium sativum L.Essential oil (bulbs)Allicin, alliin, ajoene [75]C. albicans ATCC 14053MIC8.0 μg∙mL−1>99.9% reduction8.00 μg∙mL−1[74]
IZD19.0 mm (50.0 μg∙mL−1)
Aloysia gratissima (Aff & Hook) Tronc.Essential oil (leaves)(E)-pinocamphone,
β-pinene, guaiol		C. albicans CBS 562MIC0.015 mg∙mL−112.3% inhibition1.00 mg∙mL−1[64]
MFC0.062 mg∙mL−1
Artemisia judaica L.Essential oil (aerial plant parts)Piperitone, camphor, ethyl cinnamate, chrysanthenoneC. albicans ATCC 10231MIC1.25 μg∙mL−150.0% reduction2.5 μg∙mL−1[100]
Brucea javanica (L.) Merr.Aqeuous extract (seeds)Quassinoids,
alkaloids,		C. albicans ATCC 14053-94.5% CSH reduction
79.7% adherence reduction		6.00 mg∙mL−1[101]
C. dubliniensis ATCC MYA-297590.4% CSH reduction
27.9% adherence reduction
C. glabrata ATCC 9003084.8% CSH reduction
76.8% adherence reduction
C. krusei ATCC 1424397.0% CSH reduction
67.6% adherence reduction
C. lusitaniae ATCC 6412591.1% CSH reduction
89.0% adherence reduction
C. parapsilosis ATCC 2201998.8% CSH reduction
49.0% adherence reduction
C. tropicalis ATCC 1380388.4% CSH reduction
89.9% adherence reduction
Cassia spectabilis DC.Methanol extract (leaves)(+)-spectaline; (−)-iso-6-cassine [102]C. albicans 1 (CI)MIC
IZD		6.25 mg∙mL−1
20 mm (100 mg∙mL−1)		97% inhibition6.25 mg∙mL−1[103]
C. albicans 2 (CI)MIC
IZD		6.25 mg∙mL−1
21 mm (100 mg∙mL−1)
C. albicans 3 (CI)MIC
IZD		6.25 mg∙mL−1
23 mm (100 mg∙mL−1)
Chenopodium ambrosioides L.Aqueous extract (leaves)Kaempferol, quercetinC. albicans ATCC 90028MIC0.250 mg∙mL−1>99.0% reduction1.25 mg∙mL−1[104]
MFC0.250 mg∙mL−1
Cinnamomum cassia L. J.PreslEssential oil (leaves, bark, stalk)Cinnamaldehyde, benzyl benzoate, α-pineneC. albicans ATCC 90028MIC65.5 µg∙mL−1>99.9% reduction1.00 mg∙mL−1[80]
MFC
Cinnamomum verum J.PreslEssential oil (leaves)Eugenol, benzyl benzoate, trans-caryophyllene, acetyle eugenol, linaloolC. albicans ATCC MYA-2876MIC1.0 mg∙mL−150% reduction0.15 mg∙mL−1[105]
50% inhibition1.0 mg∙mL−1
C. tropicalis ATCC 75050% reduction0.35 mg∙mL−1
50% inhibition>2.0 mg∙mL−1
C. dubliniensis ATCC MYA-64650% reduction0.2 mg∙mL−1
50% inhibition0.2 mg∙mL−1
Cinnamomum zeylanicum BlumeEssential oil (leaves)Cinnamaldehyde, cinnamyl acetate, cinnamyl benzoate [79]C. albicans ATCC 10231MIC0.1 µg∙mL−199.75% reduction1.6 µg∙mL−1[106]
MFC0.4 µg∙mL−1
IZD42.5 mm (50 µg∙mL−1)
Coriandrum sativum L.Essential oil (leaves)Decanal, trans-2-decenal, 2-decen-1-ol, cyclodecane, cis-2-dodecenalC. albicans CBS 562MIC15.6 µg∙mL−153.43% inhibition62.50 µg∙mL−1[107]
MFC31.2 µg∙mL−1
C. tropicalis CBS 94MIC31.2 µg∙mL−189.76% inhibition125 µg∙mL−1
MFC62.5 µg∙mL−1
C. krusei CBS 573MIC15.6 µg∙mL−142.13% inhibition15.62 µg∙mL−1
MFC31.2 µg∙mL−1
C. dubliniensis CBS 7987MIC31.2 µg∙mL−161.51% inhibition62.50 µg∙mL−1
MFC62.5 µg∙mL−1
C. rugosa CBS 12MIC15.6 µg∙mL−168.03% inhibition62.50 µg∙mL−1
MFC31.2 µg∙mL−1
Croton urucurana Baill.Methanol extract (stems)(epi)-catechin dimer I [108]C. albicans ATCC 10231-46.0% inhibition0.500 mg∙mL−1[109]
Cymbopogon citratus
(DC.) Stapf		Essential oil (leaves)Citral, neral, β-myrcene, geraniol [110]C. albicans ATCC 10231MIC0.1 µL∙mL−199.79% reduction6.4 µL∙mL−1[106]
MFC0.4 µL∙mL−1
IZD18.2 mm (5% v.v−1)
Ethanol extract (leaves)Citral, geraniol, neral, camphene, limonene [111]C. albicans ATCC 18804MIC0.625 mg∙mL−1>99.9% inhibition3.13 mg∙mL−1[112]
MFC2.50 mg∙mL−194.0% reduction6.25 mg∙mL−1
Cymbopogon nardus L. RendleEssential oil (leaves)Citronellal, citronellol, geraniolC. albicans ATCC 76645MIC32.0 µg∙mL−1>99.0% inhibition32.0 µg∙mL−1[113]
MFC
Cymbopogon winterianus JowittEssential oil (leaves)Citronellal, citronellol, geraniolC. albicans ATCC 90028MIC250 µg∙mL−1>99.0% reduction1.00 mg∙mL−1[80]
MFC
Cyperus articulatus L.Essential oil (bulbs)α-pinene, mustakone, α-bulneseneC. albicans CBS 562MIC0.125 mg∙mL−128.1% inhibition1.00 mg∙mL−1[112]
MFC0.500 mg∙mL−1
Eucalyptus globulus Labill.Essential oil (leaves)Hyperoside, quercitrin, myricetin [114]C. albicans ATCC 14053MFC0.219 mg∙mL−186% reduction22.5 mg∙mL−1[115]
C. tropicalis ATCC 660290.885 mg∙mL−185% reduction
C. glabrata ATCC 660320.219 mg∙mL−185.2% reduction
Houttuynia cordata ThunbEthanol extract (leaves)AldehydesC. albicans CAD1MFC>2.17 mg∙mL−170.0% reduction1.00% (v/v)[116]
Lippia sidoides Cham.Essential oil (leaves)Thymol, p-cymene, α-caryophylleneC. albicans CBS 562MIC0.250 mg∙mL−116.5% inhibition1.00 mg∙mL−1[117]
MFC0.500 mg∙mL−1
Melaleuca alternifolia (Maiden & Betche) CheelEssential oil (leaves)Terpinen-4-ol, γ-terpinene, p-cymene, α-terpinene,1,8-cineole, α-terpineol, α-pineneC. albicans ATCC 18804MIC1.95 mg∙mL−1MBEC125 mg∙mL−1[118]
Essential oil (leaves)Terpinen-4-ol, γ-terpinene, α-terpinene, terpinolene, 1,8-cineoleC. albicans ATCC 10231MIC3.40 mg∙mL−1131% adherence reduction0.75% (v/v)[119]
C. albicans SC5314MIC0.84 mg∙mL−176.0% adherence reduction
Mikania glomerata SprengEssential oil (leaves)Germacrene D, α-caryophyllene, bicyclogermacreneC. albicans CBS 562MIC0.250 mg∙mL−122.7% inhibition1.00 mg∙mL−1[117]
MFC0.250 mg∙mL−1
Piper betle L.Aqueous extract (leaves)Hydroxychavicol, cinnamoyl derivatives, luteolin, apigenin [120]C. albicans ATCC 14053-38.6% CSH reduction
61.4% adherence reduction		6.00 mg∙mL−1[101]
C. dubliniensis ATCC MYA-297578.3% CSH reduction
21.4% adherence reduction
C. glabrata ATCC 9003071.4% CSH reduction
12.4% adherence reduction
C. krusei ATCC 1424331.6% CSH reduction
56.4% adherence reduction
C. lusitaniae ATCC 6412567.5% CSH reduction
47.6% adherence reduction
C. parapsilosis ATCC 2201948.1% CSH reduction
46.5% adherence reduction
C. tropicalis ATCC 1380329.7% CSH reduction
86.9% adherence reduction
Rosmarinus officinalis L.Liposoluble extract (leaves)Carnosic acid, carnosol [121]C. albicans ATCC 18804MIC0.78 mg∙mL−199.9% reduction200 mg∙mL−1[122]
MMC3.13 mg∙mL−1
Satureja hortensis L.Essential oil (leaves and flowers)Thymol, λ-terpinene, carvacrol, p-cymeneC. albicans F81 (CI)MIC
MFC		300 µg∙mL−1
400 µg∙mL−1		91.0% inhibition
91.0% reduction		4.80 mg∙mL−1[123]
C. albicans F94 (CI)200 µg∙mL−1
300 µg∙mL−1		90.0% inhibition
80.0% reduction
C. albicans F87 (CI)300 µg∙mL−1
400 µg∙mL−1		86.0% inhibition
76.0% reduction
C. albicans F49 (CI)400 µg∙mL−1
600 µg∙mL−1		92.0% inhibition
92.0% reduction
C. albicans F82 (CI)400 µg∙mL−1
600 µg∙mL−1		89.0% inhibition
89.0% reduction
C. albicans F95 (CI)400 µg∙mL−181.0% inhibition
81.0% reduction
C. albicans F92 (CI)300 µg∙mL−1
600 µg∙mL−1		90.0% inhibition
90.0% reduction
C. albicans F60 (CI)400 µg∙mL−1
600 µg∙mL−1		80.0% inhibition
80.0% reduction
C. albicans F86 (CI)200 µg∙mL−1
300 µg∙mL−1		87.0% inhibition
87.0% reduction
C. albicans F91 (CI)300 µg∙mL−1
400 µg∙mL−1		83.0% inhibition
83.0% reduction
C. albicans F69 (CI)200 µg∙mL−1
300 µg∙mL−1		91.0% inhibition
80.0% reduction
C. albicans F1 (CI)87.0% inhibition
79.0% reduction
C. albicans F34 (CI)86.0% inhibition
91.0% reduction
C. albicans F19 (CI)90.0% inhibition
85.0% reduction
C. albicans F78 (CI)400 µg∙mL−1
600 µg∙mL−1		84.0% inhibition
84.0% reduction
Schinus terebinthifolia
Raddi.		Methanol extract (leaves)Phenolic compounds, anthraquinones, terpenoids, alkaloidsC. albicans ATCC 10231-47.0% inhibition0.007 mg∙mL−1[109]
Solidago virgaurea subsp. alpestris Waldst. & Kit. ex Willd.Aqueous extract (aerial plant parts)SaponinsC. albicans ATCC 10231NA (IZD)95.9% inhibition
92.4% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1		[98]
C. albicans IM001 (CI)96.0% inhibition
82.2% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1
C. albicans IM003 (CI)99.5% inhibition
76.3% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1
C. albicans IM007 (CI)95.1% inhibition
91.9% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1
Solidago virgaurea L. subsp. virgaurea.Aqueous extract (aerial plant parts)SaponinsC. albicans ATCC 10231NA (IZD)98.4% inhibition
77.9% reduction		0.250 mg∙mL−1
0.750 mg∙mL−1
C. albicans IM001 (CI)99.2% inhibition
91.1% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1
C. albicans IM003 (CI)97.3% inhibition
79.2% reduction 		0.250 mg∙mL−1
0.750 mg∙mL−1
C. albicans IM007 (CI)96.5% inhibition 90.9%
reduction		0.250 mg∙mL−1
0.750 mg∙mL−1
Terminalia catappa
L.		Ethanol extract (leaves)Caffeic acid, quercitrin, kaempferol, gallic acid, chlorogenic acid, isoquercitrin [124]C. albicans ATCC 90028MIC
MFC		6.25 mg∙mL−1
12.5 mg∙mL−1		>98.0% reduction62.5 mg∙mL−1[125]
n-butanol fraction from ethanol extract (leaves)C. albicans ATCC 90028MIC
MFC		250 μg∙mL−1>99.5% reduction2.50 mg∙mL−1[126]
C. glabrata ATCC 2001MIC
MFC		250 μg∙mL−1>99.0% reduction2.50 mg∙mL−1
Trachyspermum ammi (L.) SpragueAromatic water (aerial plant parts)Thymol, carvacrol, carvotanacetoneC. albicans CBS1905--95.2% inhibition0.5% (v/v)[127]
Zataria multiflora Boiss.Aqueous extract (whole plant)Thymol, hydroxyl benzoic acid, and cymene [128]C. albicans PTCC-5027MIC1.50 mg∙mL−187% reduction25 mg∙mL−1[129]
Ethanolic extract (whole plant)MIC0.84 mg∙mL−197% reduction
1 IZD: Inhibition zone diameter; MIC: Minimum inhibitory concentration; MFC: minimum fungicidal concentration; MMC: minimum microbiocidal concentration; MBIC: Minimum biofilm inhibitory concentration; MBEC: Minimum biofilm eradication concentration; NA: No activity; -: Not tested; CI: clinical isolate; CSH: Cell surface hydrophobicity.

5. Conclusions

Medicinal plants are still an untapped source of powerful natural products with great antimicrobial and/or antibiofilm potential, especially in a backdrop of increasing antibiotic resistance. This review aimed to identify medicinal plant products, such as essential oils and plant extracts for the treatment of common oral Candida infections, mainly caused by the formation of fungal biofilms. Although extracts from many medicinal plants have shown exciting results in controlling these biofilms, the most promising plant extracts were from A. sativum L., which reduced C. albicans ATCC 14053 oral biofilm formation by more than 99.9% at a concentration of 8.0 µg∙mL−1; the essential oil extracted from C. zeylanicum Blume., which showed, at a concentration of 1.6 µg∙mL−1, a reduction in oral biofilm formation by C. albicans ATCC 10231 higher than 99.75%; and the essential oil obtained from C. citratus (DC) Stapf, which exhibited a reduction in the oral biofilm formation by C. albicans ATCC 10231 greater than 99.79% at 6.4 µg∙mL−1. Interestingly, in all of these medicinal plant species, organic compounds with proven bioactive properties such as antimicrobial and antibiofilm effects were identified.
The use of essential oils and plant extracts from medicinal plants can be a great alternative to conventional antimicrobials in the treatment of fungal infections in the oral cavity since they have low levels of cytotoxicity and, to date and to our knowledge, do not induce resistance in microorganisms. However, research on the use of medicinal plants in the treatment of oral ailments remains an extremely interesting and unexplored topic, mainly due to the wide variety of plants whose phytochemical profiles are still unknown, and which will likely show good antimicrobial and antibiofilm properties.

Author Contributions

Conceptualization R.G., C.M., Â.L.; methodology R.G., C.M., Â.L., J.S.; data collection R.G., C.M., Â.L., J.S., C.F., A.B.; writing—original draft preparations R.G., C.M., J.S.; writing—review and editing I.C.F.R.F., L.B.; supervision M.J.A. All authors have read and agreed to the published version of the manuscript.

Funding

The authors wish to acknowledge financial support from the project “AquaValor—Centro de Valorização e Transferência de Tecnologia da Água” (NORTE-01-0246-FEDER-000053), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). The authors are also grateful to the Foundation for Science and Technology (FCT, Portugal) for financial support through national funds FCT/MCTES to CIMO (UIDB/00690/2020); and L. Barros is grateful for her contract through the institutional scientific employment program-contract.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouységu, L. Plant polyphenols: Chemical properties, biological activities, and synthesis. Angew. Chem. Int. Ed. Engl. 2011, 50, 586–621. [Google Scholar] [CrossRef]
  2. Daglia, M. Polyphenols as antimicrobial agents. Curr. Opin. Biotechnol. 2012, 23, 174–181. [Google Scholar] [CrossRef]
  3. Slobodníková, L.; Fialová, S.; Rendeková, K.; Kováč, J.; Mučaji, P. Antibiofilm Activity of Plant Polyphenols. Molecules 2016, 21, 1717. [Google Scholar] [CrossRef] [PubMed]
  4. Gyawali, R.; Salam, A.I. Natural products as antimicrobial agents. Food Control 2014, 46, 412–429. [Google Scholar] [CrossRef]
  5. Cushnie, T.P.T.; Lamb, A.J. Recent advances in understanding the antibacterial properties of flavonoids. Int. J. Antimicrob. Agents 2011, 38, 99–107. [Google Scholar] [CrossRef]
  6. Silva, L.N.; Zimmer, K.R.; Macedo, A.J.; Trentin, D.S. Plant Natural Products Targeting Bacterial Virulence Factors. Chem. Rev. 2016, 116, 9162–9236. [Google Scholar] [CrossRef]
  7. Donlan, R.M.; Costerton, J.W. Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms. Clin. Microbiol. Rev. 2002, 15, 167–193. [Google Scholar] [CrossRef] [Green Version]
  8. Hall-Stoodley, L.; Stoodley, P. Evolving concepts in biofilm infections. Cell. Microbiol. 2009, 11, 1034–1043. [Google Scholar] [CrossRef] [PubMed]
  9. Anderson, G.G.; O’Toole, G.A. Innate and Induced Resistance Mechanisms of Bacterial Biofilms. In Bacterial Biofilms; Romeo, T., Ed.; Springer: Berlin/Heidelberg, Germany, 2008; Volume 322, pp. 85–105. [Google Scholar]
  10. Brown, J.; Johnston, W.; Delaney, C.; Short, B.; Butcher, M.; Young, T.; Butcher, J.; Riggio, M.; Culshaw, S.; Ramage, G. Polymicrobial oral biofilm models: Simplifying the complex. J. Med. Microbiol. 2019, 68, 1573–1584. [Google Scholar] [CrossRef] [PubMed]
  11. Abusrewil, S.; Alshanta, O.A.; Albashaireh, K.; Alqahtani, S.; Nile, C.J.; Scott, J.A.; McLean, W. Detection, treatment and prevention of endodontic biofilm infections: What’s new in 2020? Crit. Rev. Microbiol. 2020, 46, 194–212. [Google Scholar] [CrossRef] [PubMed]
  12. Baumgardner, D.J. Oral Fungal Microbiota: To Thrush and Beyond. J. Patient. Cent. Res. Rev. 2019, 6, 252–261. [Google Scholar] [CrossRef] [PubMed]
  13. Awawdeh, L.; Jamleh, A.; Al Beitawi, M. The Antifungal Effect of Propolis Endodontic Irrigant with Three Other Irrigation Solutions in Presence and Absence of Smear Layer: An In Vitro Study. Iran. Edond. J. 2018, 13, 234–239. [Google Scholar] [CrossRef]
  14. Phumat, P.; Khongkhunthian, S.; Wanachantararak, P.; Okonogi, S. Comparative inhibitory effects of 4-allylpyrocatechol isolated from Piper betle on Streptococcus intermedius, Streptococcus mutans, and Candida albicans. Arch. Oral Biol. 2020, 113, 104690. [Google Scholar] [CrossRef] [PubMed]
  15. Pfaller, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 2007, 20, 133–163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Panda, A.K.; Barik, B.P. Review: Endodontic Bacterial Characterization. J. Int. Clin. Dent. Res. Organ. 2020, 12, 110–114. [Google Scholar] [CrossRef]
  17. Zhang, C.; Kuang, X.; Zhou, Y.; Peng, X.; Guo, Q.; Yang, T.; Zhou, X.; Luo, Y.; Xu, X. A Novel Small Molecule, ZY354, Inhibits Dental Caries-Associated Oral Biofilms. Antimicrob. Agents Chemother. 2019, 63, e02414–e02418. [Google Scholar] [CrossRef] [Green Version]
  18. Wu, J.; Fan, Y.; Wang, X.; Jiang, X.; Zou, J.; Huang, R. Effects of the natural compound, oxyresveratrol, on the growth of Streptococcus mutans, and on biofilm formation, acid production, and virulence gene expression. Eur. J. Oral Sci. 2020, 128, 18–26. [Google Scholar] [CrossRef]
  19. Chen, X.; Daliri, E.B.; Kim, N.; Kim, J.R.; Yoo, D.; Oh, D.H. Microbial Etiology and Prevention of Dental Caries: Exploiting Natural Products to Inhibit Cariogenic Biofilms. Pathogens 2020, 9, 569. [Google Scholar] [CrossRef]
  20. Galletti, J.; Tobaldini-Valerio, F.K.; Silva, S.; Kioshima, É.S.; Trierveiler-Pereira, L.; Bruschi, M.; Negri, M.; Estivalet Svidzinski, T.I. Antibiofilm activity of propolis extract on Fusarium species from onychomycosis. Future Microbiol. 2017, 12, 1311–1321. [Google Scholar] [CrossRef] [Green Version]
  21. Zida, A.; Bamba, S.; Yacouba, A.; Ouedraogo-Traore, R.; Guiguemdé, R.T. Anti-Candida albicans natural products, sources of new antifungal drugs: A review. J. Mycol. Med. 2017, 27, 1–19. [Google Scholar] [CrossRef]
  22. McClatchey, W.C.; Mahady, G.B.; Bennett, B.C.; Shiels, L.; Savo, V. Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources. Pharmacol. Ther. 2009, 123, 239–254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Erb, M.; Kliebenstein, D.J. Plant Secondary Metabolites as Defenses, Regulators, and Primary Metabolites: The Blurred Functional Trichotomy. Plant. Physiol. 2020, 184, 39–52. [Google Scholar] [CrossRef]
  24. Kessler, A.; Kalske, A. Plant Secondary Metabolite Diversity and Species Interactions. Annu. Rev. Ecol. Evol. Syst. 2018, 49, 115–138. [Google Scholar] [CrossRef]
  25. Hussein, R.A.; El-anssary, A.A. Plants Secondary Metabolites: The Key Drivers of the Pharmacological Actions of Medicinal Plants. In Herbal Medicine; Builders, P.F., Ed.; IntechOpen: London, UK, 2019. [Google Scholar]
  26. Gorlenko, C.L.; Kiselev, H.Y.; Budanova, E.V.; Zamyatnin, A.A., Jr.; Ikryannikova, L.N. Plant Secondary Metabolites in the Battle of Drugs and Drug-Resistant Bacteria: New Heroes or Worse Clones of Antibiotics? Antibiotics 2020, 9, 170. [Google Scholar] [CrossRef] [Green Version]
  27. Pichersky, E.; Jonathan, G. The formation and function of plant volatiles: Perfumes for pollinator attraction and defense. Curr. Opin. Plant Biol. 2002, 5, 237–243. [Google Scholar] [CrossRef]
  28. Franklin, L.U.; Cunnington, G.D.; Young, D. Terpene Based Pesticide Treatments for Killing Terrestrial Arthropods Including, Amongst Others, Lice, Lice Eggs, Mites and Ants. U.S. Patent US19990379268, 23 August 1999. [Google Scholar]
  29. Rubió, L.; Motilva, M.J.; Romero, M.P. Recent advances in biologically active compounds in herbs and spices: A review of the most effective antioxidant and anti-inflammatory active principles. Crit. Rev. Food Sci. Nutr. 2013, 53, 943–953. [Google Scholar] [CrossRef]
  30. Alu’datt, M.H.; Rababah, T.; Alhamad, M.N.; Al-Rabadi, G.J.; Tranchant, C.C.; Almajwal, A.; Kubow, S.; Alli, I. Occurrence, types, properties and interactions of phenolic compounds with other food constituents in oil-bearing plants. Crit. Rev. Food Sci. Nutr. 2018, 58, 3209–3218. [Google Scholar] [CrossRef]
  31. Carocho, M.; Ferreira, I.C.F.R. The role of phenolic compounds in the fight against cancer—A review. Anticancer Agents Med. Chem. 2013, 13, 1236–1258. [Google Scholar] [CrossRef]
  32. The Editors of Encyclopaedia Britannica. Alkaloids. In Encyclopedia of Analytical Science, 2nd ed.; Worsfold, P., Townshend, A., Colin, P., Eds.; Elsevier: Oxford, UK, 2005; pp. 56–61. [Google Scholar]
  33. Othman, L.; Sleiman, A.; Abdel-Massih, R.M. Antimicrobial Activity of Polyphenols and Alkaloids in Middle Eastern Plants. Front. Microbiol. 2019, 10, 911. [Google Scholar] [CrossRef]
  34. Roby, M.H.H.; Sarhan, M.A.; Selim, K.A.-H.; Khalel, K.I. Evaluation of antioxidant activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia officinalis L.), and marjoram (Origanum majorana L.) extracts. Ind. Crop. Prod. 2013, 43, 827–831. [Google Scholar] [CrossRef]
  35. Zielinski, A.; Haminiuki, C.; Alberti, A.; Nogueira, A.; Demiate, I.; Granato, D. A comparative study of the phenolic compounds and the in vitro antioxidant activity of different Brazilian teas using multivariate statistical techniques. Food Res. Int. 2014, 60, 246–254. [Google Scholar] [CrossRef] [Green Version]
  36. Zhao, J.G.; Yan, Q.Q.; Lu, L.Z.; Zhang, Y.Q. In vivo antioxidant, hypoglycemic, and anti-tumor activities of anthocyanin extracts from purple sweet potato. Nutr. Res. Pract. 2013, 7, 359–365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Albishi, T.; John, J.; Al-Khalifa, A.; Shahidi, F. Antioxidant, anti-inflammatory and DNA scission inhibitory activities of phenolic compounds in selected onion and potato varieties. J. Funct. Foods 2013, 5, 930–939. [Google Scholar] [CrossRef]
  38. Bachiega, T.F.; de Sousa, J.P.B.; Bastos, J.K.; Sforcin, J.M. Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine production by murine macrophages. J. Pharm. Pharmacol. 2012, 64, 610–616. [Google Scholar] [CrossRef] [PubMed]
  39. Sher, A. Antimicrobial Activity of Natural Products from Medicinal Plants. Gomal J. Med. Sci. 2004, 7, 72–78. [Google Scholar]
  40. Mulaudzi, R.B.; Ndhlala, A.R.; Kulkarni, M.G.; Finnie, J.F.; Van Staden, J. Antimicrobial properties and phenolic contents of medicinal plants used by the Venda people for conditions related to venereal diseases. J. Ethnopharmacol. 2011, 135, 330–337. [Google Scholar] [CrossRef]
  41. Mangunwardoyo, W.; Deasywati; Usia, T. Antimicrobial and identification of active compound Curcuma xanthorrhiza Roxb. Int. J. Basic Appl. Sci. 2012, 12, 69–78. [Google Scholar]
  42. Balasundram, N.; Sundram, K.; Samman, S. Phenolic compounds in plants and agri-industrial by-products: Antioxidant activity, occurrence, and potential uses. Food Chem. 2006, 99, 191–203. [Google Scholar] [CrossRef]
  43. Balange, A.K.; Benjakul, S. Effect of oxidised phenolic compounds on the gel property of mackerel (Rastrelliger kanagurta) surimi. LWT 2009, 42, 1059–1064. [Google Scholar] [CrossRef]
  44. Okumura, H. Application of phenolic compounds in plants for green chemical materials. Curr. Opin. Green Sustain. Chem. 2021, 27, 100418. [Google Scholar] [CrossRef]
  45. Alves, C.T.; Ferreira, I.C.F.R.; Barros, L.; Silva, S.; Azeredo, J.; Henriques, M. Antifungal activity of phenolic compounds identified in flowers from North Eastern Portugal against Candida species. Future Microbiol. 2014, 9, 139–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Martins, N.; Barros, L.; Henriques, M.; Silva, S.; Ferreira, I.C.F.R. In Vivo Anti-Candida Activity of Phenolic Extracts and Compounds: Future Perspectives Focusing on Effective Clinical Interventions. BioMed Res Int. 2015, 2015, 247382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Khan, M.S.A.; Ahmad, I.B. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms. J. Antimicrob. Chemother. 2011, 67, 618–621. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Lu, M.; Li, T.; Wan, J.; Li, X.; Yuan, L.; Sun, S. Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. Int. J. Antimicrob. Agents 2017, 49, 125–136. [Google Scholar] [CrossRef]
  49. Uppuluri, P.; Pierce, C.G.; López-Ribot, J.L. Candida albicans biofilm formation and its clinical consequences. Future Microbiol. 2009, 4, 1235–1237. [Google Scholar] [CrossRef] [Green Version]
  50. Cavalcanti, Y.W.; de Almeida, L.F.D.; Padilha, W.W.N. Anti-adherent activity of Rosmarinus officinalis essential oil on Candida albicans: An SEM analysis. Rev. Odonto Ciênc. 2011, 26, 139–144. [Google Scholar] [CrossRef]
  51. Onyewu, C.; Blankenship, J.R.; Del Poeta, M.; Heitman, J. Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 2003, 47, 956–964. [Google Scholar] [CrossRef] [Green Version]
  52. Leroy, O.; Bailly, S.; Gangneux, J.P.; Mira, J.P.; Devos, P.; Dupont, H.; Montravers, P.; Perrigault, P.F.; Constantin, J.M.; Guillemot, D.; et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: The AmarCAND 2 study. Ann. Intensive Care 2016, 6, 2. [Google Scholar] [CrossRef] [Green Version]
  53. Perfect, J.R. The antifungal pipeline: A reality check. Nat. Rev. Drug Discov. 2017, 16, 603–616. [Google Scholar] [CrossRef] [Green Version]
  54. Brighenti, F.L.; Salvador, M.J.; Gontijo, A.V.L.; Delbem, A.C.B.; Soares, C.P.; de Oliveira, M.A.C.; Girondi, C.M.; Yumi, K.-I.C. Plant extracts: Initial screening, identification of bioactive compounds and effect against Candida albicans biofilms. Future Microbiol. 2017, 12, 15–27. [Google Scholar] [CrossRef]
  55. Tsai, P.-W.; Chen, Y.-T.; Hsu, P.-C.; Lan, C.-Y. Study of Candida albicans and its interactions with the host: A mini review. BioMedicine 2013, 3, 51–64. [Google Scholar] [CrossRef]
  56. Bassetti, M.; Peghin, M.; Timsit, J.F. The current treatment landscape: Candidiasis. J. Antimicrob. Chemother. 2016, 71, ii13–ii22. [Google Scholar] [CrossRef]
  57. Gonzalez-Lara, M.F.; Ostrosky-Zeichner, L. Invasive Candidiasis. Semin. Respir. Crit. Care Med. 2020, 41, 3–12. [Google Scholar] [CrossRef] [PubMed]
  58. Sullivan, D.J.; Moran, G.P.; Pinjon, E.; Al-Mosaid, A.; Stokes, C.; Vaughan, C.; Coleman, D.C. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res. 2004, 4, 369–376. [Google Scholar] [CrossRef] [Green Version]
  59. Westwater, C.; Schofield, D.A.; Nicholas, P.J.; Paulling, E.E.; Balish, E. Candida glabrata and Candida albicans; dissimilar tissue tropism and infectivity in a gnotobiotic model of mucosal candidiasis. FEMS Immunol. Med. Microbiol. 2007, 51, 134–139. [Google Scholar] [CrossRef] [Green Version]
  60. McCullough, M.J.; Ross, B.C.; Reade, P.C. Candida albicans: A review of its history, taxonomy, epidemiology, virulence attributes, and methods of strain differentiation. Int. J. Oral Maxillofac. Surg. 1996, 25, 136–144. [Google Scholar] [CrossRef]
  61. Kumar, K.; Askari, F.; Sahu, M.S.; Kaur, R. Candida glabrata: A Lot More Than Meets the Eye. Microorganisms 2019, 7, 39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Warnakulasuriya, S. Burket’s oral medicine: Diagnosis and treatment. Br. Dent. J. 2003, 194. [Google Scholar] [CrossRef]
  63. Millsop, J.W.; Fazel, N. Oral candidiasis. Clin. Dermatol. 2016, 34, 487–494. [Google Scholar] [CrossRef] [PubMed]
  64. Lavaee, F.; Moshaverinia, M.; Malek-Hosseini, S.; Jamshidzade, A.; Zarei, M.; Jafarian, H.; Haddadi, P.; Badiee, P. Antifungal effect of sesame medicinal herb on Candida Species: Original study and mini-review. Braz. J. Pharm. Sci. 2019, 55. [Google Scholar] [CrossRef]
  65. Torres, S.R.; Peixoto, C.B.; Caldas, D.M.; Silva, E.B.; Akiti, T.; Nucci, M.; de Uzeda, M. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2002, 93, 149–154. [Google Scholar] [CrossRef] [PubMed]
  66. Sufiawati, I.; Pratiwi, U.; Wijaya, I.; Rusdiana, T.; Subarnas, A. The relationship between Candida albicans colonization and oral hygiene in cancer patients undergoing chemotherapy. Mater. Today Proc. 2019, 16, 2122–2127. [Google Scholar] [CrossRef]
  67. Braga, P.C.; Culici, M.; Alfieri, M.; Dal Sasso, M. Thymol inhibits Candida albicans biofilm formation and mature biofilm. Int. J. Antimicrob. Agents 2008, 31, 472–477. [Google Scholar] [CrossRef]
  68. Costa, R.C.; Cavalcanti, Y.W.; Valença, A.M.G.; de Almeida, L.F.D. Sutures modified by incorporation of chlorhexidine and cinnamaldehyde: Anti-Candida effect, bioavailability and mechanical properties. Rev. Odontol. UNESP 2019, 48. [Google Scholar] [CrossRef]
  69. Odds, F.C.; Brown, A.J.; Gow, N.A. Antifungal agents: Mechanisms of action. Trends Microbiol. 2003, 11, 272–279. [Google Scholar] [CrossRef]
  70. Raut, J.S.; Karuppayil, S.M. Phytochemicals as Inhibitors of Candida Biofilm. Curr. Pharm. Des. 2016, 22, 4111–4134. [Google Scholar] [CrossRef] [PubMed]
  71. Batiha, G.E.S.; Beshbishy, A.M.; Wasef, L.G.; Elewa, Y.H.A.; Al-Sagan, A.A.; El-Hack, M.E.A.; Taha, A.E.; Abd-Elhakim, Y.M.; Devkota, H.P. Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review. Nutrients 2020, 12, 872. [Google Scholar] [CrossRef] [Green Version]
  72. Li, Z.; Le, W.; Cui, Z. A novel therapeutic anticancer property of raw garlic extract via injection but not ingestion. Cell Death Discov. 2018, 4, 108. [Google Scholar] [CrossRef]
  73. Eidi, A.; Eidi, M.; Esmaeili, E. Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine 2006, 13, 624–629. [Google Scholar] [CrossRef]
  74. Fahim, A.; Himratul-Aznita, W.H.; Abdul-Rahman, P.S. Allium-sativum and bakuchiol combination: A natural alternative to Chlorhexidine for oral infections? Pak. J. Med. Sci. 2020, 36, 271–275. [Google Scholar] [CrossRef] [Green Version]
  75. Martins, N.; Petropoulos, S.; Ferreira, I.C.F.R. Chemical composition and bioactive compounds of garlic (Allium sativum L.) as affected by pre- and post-harvest conditions: A review. Food Chem. 2016, 211, 41–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Silva, M.L.; Bernardo, A.; de Mesquita, M.F.; Singh, J. Beneficial Uses of Cinnamon in Health and Diseases: An Interdisciplinary Approach. In The Role of Functional Food Security in Global Health; Singh, R.B., Watson, R.R., Takahashi, T., Eds.; Academic Press-Elsevier: Amsterdam, The Netherlands, 2019; pp. 565–576. [Google Scholar]
  77. Singh, A.; Deepika; Chaudhari, A.K.; Das, S.; Prasad, J.; Dwivedy, A.K.; Dubey, N.K. Efficacy of Cinnamomum cassia essential oil against food-borne molds and aflatoxin B1 contamination. Plant Biosyst. 2020, 155, 899–907. [Google Scholar] [CrossRef]
  78. Kiran, S.; Kujur, A.; Prakash, B. Assessment of preservative potential of Cinnamomum zeylanicum Blume essential oil against food borne molds, aflatoxin B1 synthesis, its functional properties and mode of action. Innov. Food. Sci. Emerg. Technol. 2016, 37, 184–191. [Google Scholar] [CrossRef]
  79. Boniface, Y.; Philippe, S.; Lima, H.; Pierre, N.; Alitonou, G.; Fatiou, T.; Sohounhloue, D. Chemical composition and Antimicrobial activities of Cinnamomum zeylanicum Blume dry Leaves essential oil against Food-borne Pathogens and Adulterated Microorganisms. Int. Res. J. Biol. Sci. 2012, 1, 18–25. [Google Scholar]
  80. Almeida, L.F.D.; Paula, J.F.; Almeida, R.V.; Williams, D.W.; Hebling, J.; Cavalcanti, Y.W. Efficacy of citronella and cinnamon essential oils on Candida albicans biofilms. Acta Odontol. Scand. 2016, 74, 393–398. [Google Scholar] [CrossRef]
  81. da Nóbrega Alves, D.; Monteiro, A.F.M.; Andrade, P.N.; Lazarini, J.G.; Abílio, G.M.F.; Guerra, F.Q.S.; Scotti, M.T.; Scotti, L.; Rosalen, P.L.; Castro, R.D.; et al. Docking Prediction, Antifungal Activity, Anti-Biofilm Effects on Candida spp., and Toxicity against Human Cells of Cinnamaldehyde. Molecules 2020, 25, 5969. [Google Scholar] [CrossRef] [PubMed]
  82. Balakrishnan, B.; Paramasivam, S.; Arulkumar, A. Evaluation of the lemongrass plant (Cymbopogon citratus) extracted in different solvents for antioxidant and antibacterial activity against human pathogens. Asian Pac. J. Trop. Dis. 2014, 4, S134–S139. [Google Scholar] [CrossRef]
  83. Han, X.; Parker, T.L. Lemongrass (Cymbopogon flexuosus) essential oil demonstrated anti-inflammatory effect in pre-inflamed human dermal fibroblasts. Biochim. Open 2017, 4, 107–111. [Google Scholar] [CrossRef] [PubMed]
  84. Liakos, I.L.; D’autilia, F.; Garzoni, A.; Bonferoni, C.; Scarpellini, A.; Brunetti, V.; Carzino, R.; Bianchini, P.; Pompa, P.P.; Athanassiou, A. All natural cellulose acetate-Lemongrass essential oil antimicrobial nanocapsules. Int. J. Pharm. 2016, 510, 508–515. [Google Scholar] [CrossRef]
  85. Taweechaisupapong, S.; Ngaonee, P.; Patsuk, P.; Pitiphat, W.; Khunkitti, W. Antibiofilm activity and post antifungal effect of lemongrass oil on clinical Candida dubliniensis isolate. S. Afr. J. Bot. 2012, 78, 37–43. [Google Scholar] [CrossRef] [Green Version]
  86. Leite, M.C.A.; Bezerra, A.P.B.; de Sousa, J.P.; Guerra, F.Q.S.; Lima, E.O. Evaluation of Antifungal Activity and Mechanism of Action of Citral against Candida albicans. Evid. Based Complement. Alternat. Med. 2014, 2014, 378280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Miron, D.; Battisti, F.; Silva, F.K.; Lana, A.D.; Pippi, B.; Casanova, B.; Gnoatto, S.; Fuentefria, A.; Mayorga, P.; Schapoval, E.E.S. Antifungal activity and mechanism of action of monoterpenes against dermatophytes and yeasts. Rev. Bras. Farmacogn. 2014, 24, 660–667. [Google Scholar] [CrossRef]
  88. Chen, Q.; Xu, S.; Wu, T.; Guo, J.; Sha, S.; Zheng, X.; Yu, T. Effect of citronella essential oil on the inhibition of postharvest Alternaria alternata in cherry tomato. J. Sci. Food Agric. 2014, 94, 2441–2447. [Google Scholar] [CrossRef]
  89. Aini, M.N.M.; Said, M.I.; Nazlina, I.; Hanina, M.N.; Ahmad, I.B. Screening for Antiviral Activity of Sweet Lemon Grass (Cymbopogon nardus (L.) Rendle) Fractions. J. Biol. Sci. 2006, 6, 507–510. [Google Scholar] [CrossRef] [Green Version]
  90. Innsan, M.F.M.F.; Shahril, M.H.; Samihah, M.S.; Asma, O.S.; Radzi, S.M.; Jalil, A.K.A.; Hanina, M.N. Pharmacodynamic properties of essential oils from Cymbopogon species. Afr. J. Pharm. Pharmacol. 2011, 5, 2676–2679. [Google Scholar] [CrossRef] [Green Version]
  91. Nakahara, K.; Alzoreky, N.; Yoshihashi, T.; Nguyen, T.; Trakoontivakorn, G. Chemical Composition and Antifungal Activity of Essential Oil from Cymbopogon nardus (Citronella Grass). Jpn. Agric. Res. Q. 2013, 37, 249–252. [Google Scholar] [CrossRef] [Green Version]
  92. Leite, B.L.S.; Bonfim, R.R.; Antoniolli, A.R.; Thomazzi, S.M.; Araújo, A.A.S.; Blank, A.F.; Estevam, C.S.; Cambui, E.V.F.; Bonjardim, L.R.; Albuquerque Jr, R.L.C.; et al. Assessment of antinociceptive, anti-inflammatory and antioxidant properties of Cymbopogon winterianus leaf essential oil. Pharm. Biol. 2010, 48, 1164–1169. [Google Scholar] [CrossRef] [PubMed]
  93. Quintans-Júnior, L.; Souza, T.; Leite, B.; Lessa, N.; Bonjardim, L.; Santos, M.; Alves, P.; Blank, A.; Antoniolli, A.R. Phytochemical screening and anticonvulsant activity of Cymbopogon winterianus Jowitt (Poaceae) leaf essential oil in rodents. Phytomedicine 2008, 15, 619–624. [Google Scholar] [CrossRef]
  94. Manh, H.D.; Hue, D.T.; Hieu, N.T.T.; Tuyen, D.T.T.; Tuyet, O.T. The Mosquito Larvicidal Activity of Essential Oils from Cymbopogon and Eucalyptus Species in Vietnam. Insects 2020, 11, 128. [Google Scholar] [CrossRef] [Green Version]
  95. Oliveira, W.; Pereira, F.; Luna, G.; Oliveira Lima, I.; Wanderley, P.; Lima, R.; Lima, E. Antifungal activity of Cymbopogon winterianus Jowitt ex bor against Candida albicans. Braz. J. Microbiol. 2011, 42, 433–441. [Google Scholar] [CrossRef] [PubMed]
  96. Zore, G.B.; Thakre, A.D.; Jadhav, S.; Karuppayil, S.M. Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle. Phytomedicine 2011, 18, 1181–1190. [Google Scholar] [CrossRef]
  97. Cornelia, F.; Tatiana, C.; Livia, U.; Dinu, M.; Ancuceanu, R. Solidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities. Biomolecules 2020, 10, 1619. [Google Scholar] [CrossRef]
  98. Chevalier, M.; Medioni, E.; Prêcheur, I. Inhibition of Candida albicans yeast–hyphal transition and biofilm formation by Solidago virgaurea water extracts. J. Med. Microbiol. 2012, 61, 1016–1022. [Google Scholar] [CrossRef] [Green Version]
  99. Ashraf, M.F.; Abd Aziz, M.; Stanslas, J.; Ismail, I.; Kadir, M. Assessment of Antioxidant and Cytotoxicity Activities of Saponin and Crude Extracts of Chlorophytum borivilianum. Sci. World J. 2013, 2013, 216894. [Google Scholar] [CrossRef] [PubMed]
  100. Abu-Darwish, M.S.; Cabral, C.; Gonçalves, M.; Cavaleiro, C.; Cruz, M.; Zulfiqar, A.; Khan, I.; Efferth, T.; Salgueiro, L. Chemical composition and biological activities of Artemisia judaica essential oil from southern desert of Jordan. J. Ethnopharmacol. 2016, 191, 161–168. [Google Scholar] [CrossRef] [PubMed]
  101. Nordin, M.A.; Wan Harun, W.H.; Abdul Razak, F. An in vitro study on the anti-adherence effect of Brucea javanica and Piper betle extracts towards oral Candida. Arch. Oral Biol. 2013, 58, 1335–1342. [Google Scholar] [CrossRef] [PubMed]
  102. Christofidis, I.; Welter, A.; Jadot, J. Spectaline and iso-6 cassine, two new piperidin 3-ol alkaloids from the leaves of cassia spectabilis. Tetrahedron 1977, 33, 977–979. [Google Scholar] [CrossRef]
  103. Torey, A.; Sasidharan, S. Anti-Candida albicans biofilm activity by Cassia spectabilis standardized methanol extract: An ultrastructural study. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 875–882. [Google Scholar]
  104. Zago, P.M.W.; Dos Santos Castelo Branco, S.J.; de Albuquerque Bogea Fecury, L.; Carvalho, L.T.; Rocha, C.Q.; Madeira, P.L.B.; de Sousa, E.M.; de Siqueira, F.S.F.; Paschoal, M.A.B.; Diniz, R.S.; et al. Anti-biofilm Action of Chenopodium ambrosioides Extract, Cytotoxic Potential and Effects on Acrylic Denture Surface. Front. Microbiol. 2019, 10, 1724. [Google Scholar] [CrossRef] [Green Version]
  105. Wijesinghe, G.K.; Maia, F.C.; de Oliveira, T.R.; de Feiria, S.N.B.; Joia, F.; Barbosa, J.P.; Boni, G.C.; Sardi, J.C.O.; Rosalen, P.L.; Höfling, J.F. Effect of Cinnamomum verum leaf essential oil on virulence factors of Candida species and determination of the in vivo toxicity with Galleria mellonella model. Mem. Inst. Oswaldo Cruz 2020, 115, e200349. [Google Scholar] [CrossRef]
  106. Choonharuangdej, S.; Srithavaj, T.; Thummawanit, S. Fungicidal and inhibitory efficacy of cinnamon and lemongrass essential oils on Candida albicans biofilm established on acrylic resin: An in vitro study. J. Prosthet. Dent. 2021, 125, 707.e701–707.e706. [Google Scholar] [CrossRef] [PubMed]
  107. Freires, I.A.; Murata, R.M.; Furletti, V.F.; Sartoratto, A.; Alencar, S.; de Alencar, S.M.; Figueira, G.M.; de Oliveira Rodrigues, J.A.; Duarte, M.C.; Rosalen, P.L. Coriandrum sativum L. (Coriander) Essential Oil: Antifungal Activity and Mode of Action on Candida spp., and Molecular Targets Affected in Human Whole-Genome Expression. PLoS ONE 2014, 9, e099086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Alves, J.J.; Inês, M.; Barreira, J.; Barros, L.; Resende, O.; Aguiar, A.; Ferreira, I.C.F.R. Phenolic Profile of Croton urucurana Baill. Leaves, Stems and Bark: Pairwise Influence of Drying Temperature and Extraction Solvent. Molecules 2020, 25, 2032. [Google Scholar] [CrossRef]
  109. Barbieri, D.S.; Tonial, F.; Lopez, P.V.; Sales Maia, B.H.; Santos, G.D.; Ribas, M.O.; Glienke, C.; Vicente, V.A. Antiadherent activity of Schinus terebinthifolius and Croton urucurana extracts on in vitro biofilm formation of Candida albicans and Streptococcus mutans. Arch. Oral Biol. 2014, 59, 887–896. [Google Scholar] [CrossRef]
  110. Ali, M.; Yusuf, M.; Nasraldeen Abdalaziz, M. GC-MS Analysis and Antimicrobial Screening of Essential Oil from Lemongrass (Cymbopogon citratus). Int. J. Pharm. Chem. 2017, 3, 72–76. [Google Scholar] [CrossRef] [Green Version]
  111. Majewska, E.; Kozłowska, M.; Gruczyńska-Sękowska, E.; Kowalska, D.; Tarnowska, K. Lemongrass (Cymbopogon citratus) Essential Oil: Extraction, Composition, Bioactivity and Uses for Food Preservation—A Review. Pol. J. Food Nutr. Sci. 2019, 69, 327–341. [Google Scholar] [CrossRef]
  112. Madeira, P.L.B.; Carvalho, L.T.; Paschoal, M.; de Sousa, E.M.; Moffa, E.; da Silva, M.A.S.; Tavarez, R.R.; Gonçalves, L. In vitro Effects of Lemongrass Extract on Candida albicans Biofilms, Human Cells Viability, and Denture Surface. Front. Cell. Infect. Microbiol. 2016, 6, 71. [Google Scholar] [CrossRef] [Green Version]
  113. Trindade, L.A.; de Araújo Oliveira, J.; de Castro, R.D.; de Oliveira Lima, E. Inhibition of adherence of C. albicans to dental implants and cover screws by Cymbopogon nardus essential oil and citronellal. Clin. Oral Investig. 2015, 19, 2223–2231. [Google Scholar] [CrossRef] [PubMed]
  114. Dezsi, Ș.; Bădărău, A.S.; Bischin, C.; Vodnar, D.C.; Silaghi-Dumitrescu, R.; Gheldiu, A.M.; Mocan, A.; Vlase, L. Antimicrobial and antioxidant activities and phenolic profile of Eucalyptus globulus Labill. and Corymbia ficifolia (F. Muell.) K.D. Hill & L.A.S. Johnson leaves. Molecules 2015, 20, 4720–4734. [Google Scholar] [CrossRef] [Green Version]
  115. Quatrin, P.M.; Verdi, C.M.; de Souza, M.E.; de Godoi, S.N.; Klein, B.; Gundel, A.; Wagner, R.; Vaucher, R.A.; Ourique, A.; Santos, R.C. Antimicrobial and antibiofilm activities of nanoemulsions containing Eucalyptus globulus oil against Pseudomonas aeruginosa and Candida spp. Microb. Pathog. 2017, 112, 230–242. [Google Scholar] [CrossRef]
  116. Sekita, Y.; Murakami, K.; Yumoto, H.; Amoh, T.; Fujiwara, N.; Ogata, S.; Matsuo, T.; Miyake, Y.; Kashiwada, Y. Preventive Effects of Houttuynia cordata Extract for Oral Infectious Diseases. BioMed Res. Int. 2016, 2016, 2581876. [Google Scholar] [CrossRef]
  117. Salete, M.F.B.; Galvo, L.C.C.; Goes, V.F.F.; Sartoratto, A.; Figueira, G.; Rehder, V.L.; Alencar, S.M.; Duarte, R.M.; Rosalen, P.L.; Duarte, M.C. Action of essential oils from Brazilian native and exotic medicinal species on oral biofilms. BMC Complement. Altern. Med. 2014, 14, 451. [Google Scholar] [CrossRef] [Green Version]
  118. Rasteiro, V.M.C.; da Costa, A.C.B.P.; Arajo, C.F.; de Barros, P.P.; Rossoni, R.D.; Anbinder, A.; Jorge, A.O.; Junqueira, J. Essential oil of Melaleuca alternifolia for the treatment of oral candidiasis induced in an immunosuppressed mouse model. BMC Complement. Altern. Med. 2014, 14, 489. [Google Scholar] [CrossRef]
  119. Tobouti, P.L.; Mussi, M.C.; Rossi, D.C.; Pigatti, F.M.; Taborda, C.P.; de Assis Taveira, L.A.; de Sousa, S.C. Influence of melaleuca and copaiba oils on Candida albicans adhesion. Gerodontology 2016, 33, 380–385. [Google Scholar] [CrossRef]
  120. Ferreres, F.; Oliveira, A.P.; Gil-Izquierdo, A.; Valentão, P.; Andrade, P.B. Piper betle leaves: Profiling phenolic compounds by HPLC/DAD-ESI/MS(n) and anti-cholinesterase activity. Phytochem. Anal. 2014, 25, 453–460. [Google Scholar] [CrossRef] [PubMed]
  121. Mena, P.; Cirlini, M.; Tassotti, M.; Herrlinger, K.A.; Dall’Asta, C.; Del Rio, D. Phytochemical Profiling of Flavonoids, Phenolic Acids, Terpenoids, and Volatile Fraction of a Rosemary (Rosmarinus officinalis L.) Extract. Molecules 2016, 21, 1576. [Google Scholar] [CrossRef]
  122. de Oliveira, J.R.; de Jesus, D.; Figueira, L.W.; de Oliveira, F.E.; Pacheco Soares, C.; Camargo, S.E.; Jorge, A.O.; de Oliveira, L.D. Biological activities of Rosmarinus officinalis L. (rosemary) extract as analyzed in microorganisms and cells. Exp. Biol. Med. 2017, 242, 625–634. [Google Scholar] [CrossRef] [Green Version]
  123. Sharifzadeh, A.; Khosravi, A.; Ahmadian, S. Chemical composition and antifungal activity of Satureja hortensis L. essentiall oil against planktonic and biofilm growth of Candida albicans isolates from buccal lesions of HIV(+) individuals. Microb. Pathog. 2016, 96, 1–9. [Google Scholar] [CrossRef]
  124. Oyeleye, S.I.; Adebayo, A.A.; Ogunsuyi, O.B.; Dada, F.A.; Oboh, G. Phenolic profile and Enzyme Inhibitory activities of Almond (Terminalia catappa) leaf and Stem bark. Int. J. Food Prop. 2018, 20, S2810–S2821. [Google Scholar] [CrossRef] [Green Version]
  125. Machado-Gonçalves, L.; Tavares-Santos, A.; Santos-Costa, F.; Soares-Diniz, R.; Câmara-de-Carvalho-Galvão, L.; Martins-de-Sousa, E.; Beninni-Paschoal, M.A. Effects of Terminalia catappa Linn. Extract on Candida albicans biofilms developed on denture acrylic resin discs. J. Clin. Exp. Dent. 2018, 10, e642–e647. [Google Scholar] [CrossRef] [PubMed]
  126. Gonçalves, L.; Madeira, P.L.B.; Diniz, R.; Nonato, R.F.; de Siqueira, F.S.F.; de Sousa, E.M.; Farias, D.; Rocha, F.M.G.; Rocha, C.H.L.; Lago, A.D.N.; et al. Effect of Terminalia catappa Linn. on Biofilms of Candida albicans and Candida glabrata and on Changes in Color and Roughness of Acrylic Resin. J. Evid. Based Complement. Altern. Med. 2019, 2019, 7481341. [Google Scholar] [CrossRef] [PubMed]
  127. Arabi Monfared, A.; Ayatollahi Mousavi, S.A.; Zomorodian, K.; Mehrabani, D.; Iraji, A.; Moein, M.R. Trachyspermum ammi aromatic water: A traditional drink with considerable anti-Candida activity. Curr. Med. Mycol. 2020, 6, 1–8. [Google Scholar] [CrossRef] [PubMed]
  128. Shaiq Ali, M.; Saleem, M.; Ali, Z.; Ahmad, V.U. Chemistry of Zataria multiflora (Lamiaceae). Phytochemistry 2000, 55, 933–936. [Google Scholar] [CrossRef]
  129. Rahimi, G.; Khodavandi, A.; Janesar, R.; Alizadeh, F.; Yaghobi, R.; Sadri, F. Evaluation of Antifungal Effects of Ethanolic and Aqueous Extracts of Zataria Multiflora Herb in the Pathogenic Yeast Candida albicans Biofilm Inhibition. J. Pure Appl. Microbiol. 2014, 8, 4559–4564. [Google Scholar]
Antibiotics 10 01142 g001 550
Figure 1. Mechanisms of action of phytocompounds against Candida spp. (Created with BioRender.com).
Figure 1. Mechanisms of action of phytocompounds against Candida spp. (Created with BioRender.com).
Antibiotics 10 01142 g001
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Guimarães, R.; Milho, C.; Liberal, Â.; Silva, J.; Fonseca, C.; Barbosa, A.; Ferreira, I.C.F.R.; Alves, M.J.; Barros, L. Antibiofilm Potential of Medicinal Plants against Candida spp. Oral Biofilms: A Review. Antibiotics 2021, 10, 1142. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10091142

AMA Style

Guimarães R, Milho C, Liberal Â, Silva J, Fonseca C, Barbosa A, Ferreira ICFR, Alves MJ, Barros L. Antibiofilm Potential of Medicinal Plants against Candida spp. Oral Biofilms: A Review. Antibiotics. 2021; 10(9):1142. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10091142

Chicago/Turabian Style

Guimarães, Rafaela, Catarina Milho, Ângela Liberal, Jani Silva, Carmélia Fonseca, Ana Barbosa, Isabel C. F. R. Ferreira, Maria José Alves, and Lillian Barros. 2021. "Antibiofilm Potential of Medicinal Plants against Candida spp. Oral Biofilms: A Review" Antibiotics 10, no. 9: 1142. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10091142

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop